JOURNAL of
ONCOLOGICAL
SCIENCES

LETTER TO THE EDITOR

There are Two Ways of Spreading Light: To Be the Candle or the Mirror That Reflects It
Received Date : 17 Mar 2021
Accepted Date : 29 Apr 2021
Available Online : 25 May 2021
Doi: 10.37047/jos.2021-83165 - Article's Language: EN
J Oncol Sci. 2021;7(2):39-41
This is an open access article under the CC BY-NC-ND license
ABSTRACT
The statistical analysis applies to a group of individuals and not a single individual. Similar to other cancers, triple-negative breast cancer (TNBC) has a completely different biology; therefore, TNBCs cannot be judged to have a poor prognosis. Apart from receiving the right treatment, the psychological state, frame of mind, and positive perspectives are also important for a patient with cancer. Patients who are motivated and optimistic better adapt to their treatments. A patient with cancer should be aware of the chances of completely curing the disease. This increases their resilience during treatment leading to a healthy lifestyle during the follow-up period.
REFERENCES
  1. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40(11):1797-1810. [Crossref]  [PubMed]  [PMC] 
  2. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012; 118(22):5463-5472. [Crossref]  [PubMed]  [PMC] 
  3. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-4434. [Crossref]  [PubMed] 
  4. Reddy SM, Barcenas CH, Sinha AK, et al. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer. 2018;118(1):17-23. [Crossref]  [PubMed]  [PMC] 
  5. Cossetti RJ, Tyldesley SK, Speers CH, Zheng Y, Gelmon KA. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol. 2015;33(1):65-73. [Crossref]  [PubMed] 
  6. Tečić Vuger A, Šeparović R, Vazdar L, et al. Characteristics and prognosis of triple-negative breast cancer patients: a croatian single institution retrospective cohort study. Acta Clin Croat. 2020;59(1):97-108. [Crossref]  [PubMed]  [PMC] 
  7. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival. Radiol Oncol. 2011;45(1):46-52. [Crossref]  [PubMed]  [PMC] 
  8. Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927-935. [Crossref]  [PubMed]  [PMC] 
  9. Pan H, Gray R, Braybrooke J, et al; EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-1846. [Crossref]  [PubMed]  [PMC]